ICON Public Limited Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
July 26, 2023 at 04:15 pm EDT
ICON Public Limited Company reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 2,020.25 million compared to USD 1,935.19 million a year ago. Net income was USD 115.6 million compared to USD 115.73 million a year ago. Basic earnings per share from continuing operations was USD 1.41 compared to USD 1.42 a year ago. Diluted earnings per share from continuing operations was USD 1.4 compared to USD 1.41 a year ago.
For the six months, sales was USD 3,998.83 million compared to USD 3,836.96 million a year ago. Net income was USD 232.25 million compared to USD 227.7 million a year ago. Basic earnings per share from continuing operations was USD 2.84 compared to USD 2.8 a year ago. Diluted earnings per share from continuing operations was USD 2.81 compared to USD 2.76 a year ago.
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors. Its sectors include Biosimilars, Biotech, Government and public health solutions, medical devices, pharmaceuticals and the IVDR journey.